Floatz logo

Cytosin-Arabinosid

Blasts 10 Percent or More of Bone Marrow Nucleated Cells

Sumithira VasuPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Blasts 10 Percent or More of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3BB
Midostaurin
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3B
METHOTREXATE
Fred Hutchinson Cancer Center
Phase 2B
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B

View all 29 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →